Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | CDK1 | P06493 | 1/20 | 0.71 |
| ▸ | NEK2 | P51955 | 1/20 | 0.71 |
| ▸ | PLK1 | P53350 | 1/20 | 0.71 |
| ▸ | EED | O75530 | 3/20 | 0.41 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.41 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.41 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.41 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 6/20 | 0.40 |
| ▸ | TDO2 | P48775 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19198458 | 1.00 | APP (1.00) | APPPIK3CAAURKACDK1NEK2 | |
| SCHEMBL12162245 | 1.00 | APP (1.00) | APPPIK3CAAURKACDK1NEK2 | |
| SCHEMBL12162279 | 1.00 | APP (1.00) | APPPIK3CAAURKACDK1NEK2 | |
| SCHEMBL12104122 | 0.90 | APP (0.81) | APPPIK3CAAURKACDK1NEK2 | |
| SCHEMBL19194047 | 0.83 | APP (0.71) | APPPIK3CAAURKACDK1NEK2 | |
| Demethoxyviridin SCHEMBL29745916 | 0.83 | APP (1.00) | APPPIK3CAAURKACDK1NEK2 | |
| Demethoxyviridin SCHEMBL12162246 | 0.83 | APP (1.00) | APPPIK3CAAURKACDK1NEK2 | |
| Demethoxyviridin SCHEMBL12464244 | 0.83 | APP (1.00) | APPPIK3CAAURKACDK1NEK2 | |
| SCHEMBL20199947 | 0.81 | APP (0.68) | APPPIK3CAAURKACDK1NEK2 | |
| SCHEMBL8226303 | 0.81 | APP (0.68) | APPPIK3CAAURKACDK1NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20090274739-A1 | METHODS AND COMPOSITIONS FOR TREATING NEOINTIMAL HYPERPLASIA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | APP 2035/4885PIK3CA 4464/4885AURKA 2444/4885 |
| US-20090274739-A1 | METHODS AND COMPOSITIONS FOR TREATING NEOINTIMAL HYPERPLASIA | MTOR, RICTOR, RPTOR | APP 3190/4885PIK3CA 6/4885AURKA 3941/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | APP 2035/4885PIK3CA 4464/4885AURKA 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.